GH Stock Overview
A precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Guardant Health, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$26.74 |
52 Week High | US$41.06 |
52 Week Low | US$15.81 |
Beta | 1.13 |
11 Month Change | -18.97% |
3 Month Change | 2.22% |
1 Year Change | -30.04% |
33 Year Change | -78.81% |
5 Year Change | -69.45% |
Change since IPO | -16.96% |
Recent News & Updates
Recent updates
Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen
Aug 21Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce
Jul 31Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 12Guardant: Double-Digit Sales Projections Come At A Cost
Jun 06Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?
Jun 04Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%
May 14Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Mar 29With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For
Jan 21Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Nov 20Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 26A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)
Sep 05Is Guardant Health (NASDAQ:GH) A Risky Investment?
Aug 15A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)
May 28Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Apr 05Is Guardant Health (NASDAQ:GH) Using Too Much Debt?
Dec 28Guardant: Saving Lives One Blood Test At A Time
Oct 16Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt
Aug 15Shareholder Returns
GH | US Healthcare | US Market | |
---|---|---|---|
7D | -5.8% | 1.2% | 0.1% |
1Y | -30.0% | 13.9% | 24.9% |
Return vs Industry: GH underperformed the US Healthcare industry which returned 14.1% over the past year.
Return vs Market: GH underperformed the US Market which returned 25.9% over the past year.
Price Volatility
GH volatility | |
---|---|
GH Average Weekly Movement | 9.0% |
Healthcare Industry Average Movement | 7.0% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GH's share price has been volatile over the past 3 months.
Volatility Over Time: GH's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 1,774 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
Guardant Health, Inc. Fundamentals Summary
GH fundamental statistics | |
---|---|
Market cap | US$3.57b |
Earnings (TTM) | -US$490.76m |
Revenue (TTM) | US$643.81m |
5.1x
P/S Ratio-6.7x
P/E RatioIs GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GH income statement (TTM) | |
---|---|
Revenue | US$643.81m |
Cost of Revenue | US$257.85m |
Gross Profit | US$385.96m |
Other Expenses | US$876.72m |
Earnings | -US$490.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.99 |
Gross Margin | 59.95% |
Net Profit Margin | -76.23% |
Debt/Equity Ratio | -70,753.6% |
How did GH perform over the long term?
See historical performance and comparison